Artery Embolization for Knee Osteoarthritis
(GRAVITY Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this clinical trial is to determine whether genicular artery embolization (GAE) is an effective way to treat knee pain from osteoarthritis. Pain from arthritis is often due to underlying inflammation in the joint. The inflammation is associated with increased abnormal blood flow going to the specific area of pain. If the investigator can reduce the blood flow, the inflammation can be reduced and the pain can be controlled. The GAE procedure is an experimental procedure to decrease the blood flow (embolize) to the specific region of the knee that is causing the pain. This will be done by infusing microscopic spheres into the specific blood vessel (genicular artery) supplying the area of pain in the knee. This is done through a procedure which is called an angiogram, which is done entirely through a pinhole at the creased of the thigh, using twilight (conscious) sedation. The investigators have already completed an initial trial at UCLA, and shown that this procedure is safe and effective. The purpose of this new trial is to compare outcomes of people undergoing the GAE procedure to those who do not undergo the procedure. A total of 100 patients will be enrolled, and 2/3 of the patients will be randomly selected to undergo the GAE procedure. 1/3 will not undergo the procedure. This is known as a randomized trial. During the trial, all subjects will also get MRIs and fluid withdrawn from their knee joints at various timepoints in order to precisely figure out how the procedure works on a closer (microscopic) level.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial requires participants to have failed conservative treatments like NSAIDs or steroid injections, it might be possible to continue some medications. Please consult with the trial coordinators for specific guidance.
What data supports the effectiveness of the treatment Genicular Artery Embolization for knee osteoarthritis?
Research shows that Genicular Artery Embolization (GAE) is a promising treatment for knee osteoarthritis, as it helps reduce pain by decreasing blood flow to inflamed areas in the knee. Studies, including systematic reviews and meta-analyses, suggest that GAE can be effective for patients whose knee pain does not improve with other treatments.12345
Is genicular artery embolization (GAE) safe for treating knee osteoarthritis?
How is genicular artery embolization different from other treatments for knee osteoarthritis?
Research Team
Siddharth A Padia, MD
Principal Investigator
University of California, Los Angeles
Eligibility Criteria
This trial is for adults aged 40-79 with moderate to severe knee pain from osteoarthritis, who haven't had success with standard treatments like NSAIDs or joint injections. Participants should have a Kellgren-Lawrence score >2 and be ineligible for or refuse surgery. Exclusions include certain medical conditions, allergies, pregnancy, recent smoking history, and previous knee replacements.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo genicular artery embolization (GAE) or are observed without intervention. GAE involves infusing microspheres into the genicular artery to reduce blood flow and inflammation.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with evaluations including MRI, serum and joint aspiration, and clinical assessments.
Crossover
Participants in the observation group have the option to crossover to the GAE treatment arm after 6 months, with follow-up evaluations similar to initial GAE subjects.
Treatment Details
Interventions
- Genicular Artery Embolization (Embolization Agent)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
Dr. Thomas Rando
University of California, Los Angeles
Chief Medical Officer since 2023
MD from UCLA
Amir Naiberg
University of California, Los Angeles
Chief Executive Officer since 2024
JD from UCLA
Varian Medical Systems
Industry Sponsor
Dow R. Wilson
Varian Medical Systems
Chief Executive Officer since 2012
MBA from Dartmouth's Amos Tuck School of Business, BA from Brigham Young University
Dr. Deepak Khuntia
Varian Medical Systems
Chief Medical Officer since 2020
MD from the University of Cambridge, PhD from the University of Leicester